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729Abstracts
OBJECTIVES: To describe therapy with a Betalactam antibiotic
versus dual therapy with a Betalactam and aminoglycoside treat-
ment regimens in ICU patients with Pseudomonas aeruginosa
nosocomial pneumonia and to evaluate treatment outcomes of
the two groups. METHODS: We retrospectively identiﬁed adult
patients admitted to a non-transplant ICU between August 1,
1999 and August 1, 2003 with documented Pseudomonas aerug-
inosa pneumonia. Patients had to receive at least 7 days of
therapy with an anti-pseudomonal antibiotic to be included.
Data collected included patient, clinical, treatment, and outcome
related details. Independent sample t-test, chi-square and multi-
ple regression analysis was used to evaluate the outcomes of the
patients according to antibiotic groups. RESULTS: A total of 389
patients were identiﬁed with Pseudomonas aeruginosa pneumo-
nia. Of these, 208 (53%) were on Betalactam ± ﬂuroquinolones
(Group 1) and 181 (47%) were on Betalactam and aminoglyco-
side ± ﬂuroquinolones (Group 2). The mean age of patients was
63.1 and 55.4 years in Groups 1 & 2 respectively (p < 0.001).
There was no signiﬁcant difference in the distribution of gender
and race between groups. Group 2 patients had more co-mor-
bidities compared to Group 1. The mean length of antibiotic
therapy in Group 1 was 24.77 and Group 2 52. Seventy-nine
days (p < 0.001) and mean ICU length of stay was 27.6 and 55.2
days in Groups 1 & 2 respectively. The mortality in Group 1
was 51 (24.5%) and in Group 2, it was 65 (35.9%) (p = 0.014).
CONCLUSIONS: The mean length of therapy, ICU length of
stay and mortality are signiﬁcantly lower in monotherapy com-
pared to combination antibiotic treatment group.
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OBJECTIVES: To describe the management of CB and COPD
at stages 1 to 3 (SPLF classiﬁcation, 1997) and to assess its cost
in France. METHODS: In total, 409 CB and COPD patients
were enrolled in the Broncheco cohort from November 2000 to
October 2003 by 10 hospital chest physicians (HP), 50 private
chest physicians (PP) and 63 general practitioners (GP). The
cohort was followed for 1 year with data collection every 3
months: socio-demographic data, medical history and disease
management (medication, oxygen, medical visits, medical pro-
cedures, hospitalisations and transportation). Inpatient costs
were evaluated using the French Diagnosis-Related Groups and
outpatient costs using the French nomenclature. Costs were
expressed in 2003 Euro, according to the French societal per-
spective. Non-parametric statistical analysis was performed.
RESULTS: In total, 316 patients were analysed (random drop-
out was tested) with a mean age of 65 years, a history of the
disease of 8 years, 75% were male and 37% were current
smokers. The distribution in stages was: 21.5%, 42.1%, 22.8%
and 13.6% respectively in stages 1, 2a, 2b, and 3. The annual
cost (both medical and non-medical) was 794€, 1936€, 3938€
and 7706€ respectively for stages 1, 2a, 2b and 3 (p < 0.001).
The proportion of outpatient care in total cost decreased when
stage of disease increased (94%, 70%, 63% and 62% respec-
tively) while the proportion of inpatient care increased (6%,
30%, 37%, 38% respectively). For a same stage of disease, the
costs were higher for HP, lower for PP and the lowest for the GP.
High correlations between cost and age, length of disease and
number of exacerbations were observed: 0.21, 0.23 and 0.49
respectively (p < 0.001). CONCLUSIONS: These results showed
that the cost of COPD was considerably greater in patient with
advanced stage of disease. This would suggest the pertinence of
early management of disease.
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OBJECTIVES: The aim of this study was to collect comparable
and reliable data on the antibiotic consumption in Slovakia
during the period 1998–2002. The special interest was paid to
the trend of the macrolides usage and the resistance of Str.pyo-
genes. Antibiotic treatment and the pharmacoeconomic analysis
of tonsillitis treatment was evaluated. METHODS: For the
period 1998–2002, data for the ambulatory and hospital care
were collected following the ATC/DDD classiﬁcation. The results
were expressed in the numbers of the packages, ﬁnance units
(SKK) and Deﬁned Daily Doses per 1000 inhabitants per day
(DID). RESULTS: The collected data showed very high con-
sumption of the antibiotic in Slovakia. Comparing to the pub-
lished international data it was one of the highest consumers of
antibiotics in Europe. The amount of packages used during the
period 1998–2002 has decreasing tendency. Antibiotic usage
expressed in DID showed moderate decrease. Consumption of
macrolides was increasing during the studied period. Usage of
drugs containing erythromycin and roxithromycin showed sig-
niﬁcant decrease. However, the usage of the drugs containing
clarythromycin and azithromycin showed statistically important
increase (p < 0.001). Different therapeutic procedures were clas-
siﬁed by pharmacoeconomical method of the cost-minimization
analysis. CONCLUSIONS: According to the results of this
analysis, the most effective treatment of tonsillitis was phe-
noxymethylpenicillin 15.30 SKK and penamecillin 18.50 SKK.
Usage of these drugs for the treatment is efﬁcient and economi-
cally convenient (p < 0.001). According to the direct cost analy-
sis, 52.2% of costs used for the treatment of tonsillitis was
“wasted”. Wrong antibiotics were chosen in case of 58.5% of
the patients.
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OBJECTIVES: Inpatient treatment of community-acquired
pneumonia (CAP) is generally non-invasive and therefore the
ﬁnancial burden for hospitals is dependent from length-of-stay.
A fast recovery of the patients shows the need of rapid acting
antibiotic treatment, especially under the German DRG-
reimbursement system. This study investigated costs and charges
of patients with CAP from the hospitals’ perspective. The new
gyrase inhibitor moxiﬂoxacin was compared to standard antimi-
crobial therapy of the participating hospitals. METHODS: The
